Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure‐Response Analyses Underutilized?
Open Access
- 18 January 2019
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 8 (3) , 138-145
Abstract
The use of model‐based drug development (MBDD) has been demonstrated to improve the efficiency of clinical trial design. However, MBDD complexity can limit its use, particularly early in clinical development. In this tutorial, a simple and generalizable exposure‐response analysis approach to determine the power for dose‐ranging studies is presented and described. We identified situations in which higher power and sample size reduction is achieved by utilizing the exposure‐response powering methodology compared with conventional power calculations.Keywords
Funding Information
- AbbVie
This publication has 11 references indexed in Scilit:
- Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance studyInvestigational New Drugs, 2016
- Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2015
- Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysisBritish Journal of Clinical Pharmacology, 2015
- Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First‐in‐Patient Study Designs in PsoriasisCPT: Pharmacometrics & Systems Pharmacology, 2013
- Model based design and analysis of phase II HIV-1 trialsJournal of Pharmacokinetics and Pharmacodynamics, 2013
- Dose finding by concentration-response versus dose-response: a simulation-based comparisonEuropean Journal of Clinical Pharmacology, 2013
- Comparisons of Analysis Methods for Proof‐of‐Concept TrialsCPT: Pharmacometrics & Systems Pharmacology, 2013
- Prediction of Exposure–Response Relationships to Support First-in-Human Study DesignThe AAPS Journal, 2010
- Evaluating potential benefits of dose–exposure–response modeling for dose findingPharmaceutical Statistics, 2009
- Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s DiseaseThe AAPS Journal, 2009